Ramius Advisors’s Biotech Acquisition Company Warrant BIOTW Stock Holding History

Ramius Advisors’s Portfolio BIOTW Stock Details BIOTW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-569,526	Closed	-$36.4K	–	174
2022 Q4	$36.4K	Buy	569,526 +1,540	+0.3%	+$59	0.03%	28
2022 Q3	$34K	Hold	567,986	–	–	0.02%	54
2022 Q2	$51K	Buy	+567,986	New	+$117K	0.03%	63
2022 Q1	–	Sell	-452,674	Closed	-$299K	–	238
2021 Q4	$299K	Sell	452,674 -171,199	-27%	-$119K	0.1%	128
2021 Q3	$412K	Buy	623,873 +122,047	+24%	+$90.8K	0.25%	66
2021 Q2	$432K	Buy	+501,826	New	+$349K	0.16%	87

Ramius Advisors's BIOTW Position: Q1 2023 in Review

Ramius Advisors sold out of Biotech Acquisition Company Warrant (BIOTW) in Q1 2023, closing a stake of 569,526 shares — an estimated $36.4K sold.

Ramius Advisors first reported a position in BIOTW in Q2 2021 and held it in 6 quarters. The position peaked at $432K in Q2 2021. 0 funds tracked by Wall St. Rank hold BIOTW as of Q1 2023.

Ramius Advisors reported no remaining Biotech Acquisition Company Warrant position as of Q1 2023 after selling out during the quarter.
Ramius Advisors sold 569,526 Biotech Acquisition Company Warrant shares in Q1 2023, an estimated $36.4K.
Ramius Advisors first reported a position in Biotech Acquisition Company Warrant in Q2 2021 and held it in 6 quarters.
Ramius Advisors's Biotech Acquisition Company Warrant position peaked at $432K in Q2 2021.
0 funds tracked by Wall St. Rank held Biotech Acquisition Company Warrant as of Q1 2023.

Based on Ramius Advisors's 13F filing for Q1 2023, filed 11 May 2023.